Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2013

View Archived Issues

Novartis develops new apoptosis regulators

CHF-5074 shows promising clinical efficacy in MCI

Gene linked to albuminuria in rat model

Tau-based immunotherapy for Alzheimer's disease described

LASSbio-1359 reverses development of PAH in rats

Dupilumab leads to improvements in eosinophilic asthma in phase IIa study

Daiichi Sankyo reports on in vivo studies of beta-amyloid peptide vaccine

Researchers develop novel transgenic mouse models of migraine-related disorders

Phase II study planned for CF-101 in uveitis

DSMB approves progress in three Advanced Cell Technology trials

FDA grants orphan designation to LJPC-0712 in Niemann-Pick type C disease

Adynxx receives FDA fast track designation for chronic pain treatment AYX1

ELND-005 granted FDA fast track designation for NPS in Alzheimer's disease

Spectrum Pharmaceuticals gains Marqibo with Talon Therapeutics acquisition

FDA accepts resubmission of NDA for Northera

Alkermes commences phase II study of broad-spectrum oral antipsychotic candidate

Compugen reveals new infrastructure platform for antibody discovery

New cationic polypeptides designed at the University of Minnesota

Rexahn in-licenses oncology drug delivery platform from University of Maryland, Baltimore

Novira Therapeutics prepares novel agents for HBV infection

Team of researchers in Brazil develop new vaccines for Brucella infection

Janssen and Pepscan patent novel polypeptide HIV fusion inhibitors

Novel lisuride analogues disclosed by MAP Pharmaceuticals, now part of Allergan

Alexion commences phase I trial of treatment candidate for MoCD

Recruitment begins in Boehringer Ingelheim's phase I trial of BI-409306

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....